Mercer Global Advisors
AZN icon

Mercer Global Advisors’s AstraZeneca AZN Stock Holding History

Mercer Global Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14M Sell
73,904
-2,492
-3% -$469K 0.02% 462
2026
Q1 		$15.1M Buy
76,396
+11,757
+18% +$2.27M 0.02% 390
2025
Q4 		$11.8M Buy
64,639
+155
+0.2% +$27.2K 0.02% 449
2025
Q3 		$9.89M Sell
64,484
-3,265
-5% -$494K 0.02% 464
2025
Q2 		$9.47M Sell
67,749
-14,505
-18% -$2.03M 0.02% 393
2025
Q1 		$12.1M Buy
82,254
+2,192
+3% +$317K 0.03% 317
2024
Q4 		$10.5M Buy
+80,062
New +$11.2M 0.03% 348
2024
Q1 		– Sell
-65,465
Closed -$8.82M – 2003
2023
Q4 		$8.82M Sell
65,465
-5,043
-7% -$656K 0.03% 333
2023
Q3 		$9.55M Buy
70,508
+9,226
+15% +$1.26M 0.04% 279
2023
Q2 		$8.77M Buy
61,282
+3,103
+5% +$457K 0.03% 322
2023
Q1 		$8.08M Buy
58,179
+119
+0.2% +$16K 0.04% 318
2022
Q4 		$7.87M Buy
58,060
+8,270
+17% +$1.04M 0.04% 320
2022
Q3 		$5.46M Buy
49,790
+121
+0.2% +$15.3K 0.03% 359
2022
Q2 		$6.56M Buy
49,669
+2,772
+6% +$364K 0.04% 296
2022
Q1 		$6.22M Buy
46,897
+2,225
+5% +$267K 0.04% 329
2021
Q4 		$5.2M Buy
44,672
+5,638
+14% +$663K 0.03% 362
2021
Q3 		$4.69M Buy
39,034
+15,969
+69% +$1.86M 0.03% 365
2021
Q2 		$2.76M Buy
23,065
+3,645
+19% +$400K 0.02% 469
2021
Q1 		$1.93M Buy
19,420
+2,604
+15% +$262K 0.02% 531
2020
Q4 		$1.68M Sell
16,816
-524
-3% -$55.5K 0.02% 468
2020
Q3 		$1.9M Buy
17,340
+2,358
+16% +$262K 0.03% 397
2020
Q2 		$1.58M Buy
14,982
+160
+1% +$16.5K 0.03% 371
2020
Q1 		$1.32M Buy
14,822
+1,428
+11% +$134K 0.03% 402
2019
Q4 		$1.34M Buy
13,394
+989
+8% +$93.1K 0.03% 443
2019
Q3 		$1.1M Buy
12,405
+1,930
+18% +$167K 0.03% 458
2019
Q2 		$865K Buy
10,475
+798
+8% +$62.6K 0.02% 503
2019
Q1 		$782K Buy
+9,677
New +$763K 0.03% 485

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Mercer Global Advisors's AZN Position: Q2 2026 in Review

Mercer Global Advisors reduced its AstraZeneca (AZN) stake by 3.3% in Q2 2026, selling an estimated $469K and leaving 73,904 shares worth $14M. The position accounts for 0.02% of the portfolio, ranked #462.

Mercer Global Advisors first reported a position in AZN in Q1 2019 and has held it in 27 quarters since. The position peaked at $15.1M in Q1 2026. 1,504 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Mercer Global Advisors held 73,904 shares of AstraZeneca worth $14M as of Q2 2026.
  • Mercer Global Advisors sold 2,492 AstraZeneca shares in Q2 2026, an estimated $469K.
  • AstraZeneca made up 0.02% of Mercer Global Advisors's portfolio in Q2 2026, its #462 holding.
  • Mercer Global Advisors first reported a position in AstraZeneca in Q1 2019 and has held it in 27 quarters since.
  • Mercer Global Advisors's AstraZeneca position peaked at $15.1M in Q1 2026.
  • 1,504 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.